<DOC>
	<DOCNO>NCT00928837</DOCNO>
	<brief_summary>The purpose study compare efficacy safety flavocoxid ( Limbrel ) Naproxen placebo OA knee .</brief_summary>
	<brief_title>Study Flavocoxid ( Limbrel ) Versus Naproxen Subjects With Moderate-Severe Osteoarthritis Knee</brief_title>
	<detailed_description>To compare efficacy , safety , quality life economic impact flavocoxid v naproxen .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Major inclusi√≥n criterion : 1 . Adults either gender , age 3585 , general good health 2 . Diagnosed OA knee , KL Grade 23 3 . History positive response NSAID 's COX2 inhibitor 4 . Able willing discontinue medicinal OA therapy length study ( subject may continue low dose aspirin cardioprotection ) 5 . Females child bear potential must use acceptable method birth control Major exclusion criterion : 1 . Unwilling unable read sign inform consent document 2 . Pregnant nursing woman 3 . History severe cardiovascular disease include , limited chronic angina , congestive heart failure , uncontrolled hypertension , acute myocardial infarction within past year 4 . KL grade 1 4 OA target knee 5. chronic bleed disorder present use anticoagulants 6 . History upper GI bleed past 5 year 7 . Significant renal disease include nephrotic syndrome , proteinuria &gt; 1 gm/24 hr serum Creatinine &gt; 2.0 8 . Any arthritic disease potential affect knee course study 9 . Any condition might confound evaluation target joint include , limited , bursitis , tendonitis internal derangement knee , gait disturbance ( e.g . mechanical , neurological condition disorder back ) , fibromyalgia , polyneuropathies , etc .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>